228 related articles for article (PubMed ID: 12065335)
1. Factors affecting the incidence of Stenotrophomonas maltophilia isolation in cystic fibrosis.
Graff GR; Burns JL
Chest; 2002 Jun; 121(6):1754-60. PubMed ID: 12065335
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for emergence of Stenotrophomonas maltophilia in cystic fibrosis.
Talmaciu I; Varlotta L; Mortensen J; Schidlow DV
Pediatr Pulmonol; 2000 Jul; 30(1):10-5. PubMed ID: 10862157
[TBL] [Abstract][Full Text] [Related]
3. Case-control study of Stenotrophomonas maltophilia acquisition in cystic fibrosis patients.
Marchac V; Equi A; Le Bihan-Benjamin C; Hodson M; Bush A
Eur Respir J; 2004 Jan; 23(1):98-102. PubMed ID: 14738239
[TBL] [Abstract][Full Text] [Related]
4. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis.
Moss RB
Chest; 2002 Jan; 121(1):55-63. PubMed ID: 11796432
[TBL] [Abstract][Full Text] [Related]
5. Chronic Stenotrophomonas maltophilia infection and exacerbation outcomes in cystic fibrosis.
Waters V; Atenafu EG; Salazar JG; Lu A; Yau Y; Matukas L; Tullis E; Ratjen F
J Cyst Fibros; 2012 Jan; 11(1):8-13. PubMed ID: 21849265
[TBL] [Abstract][Full Text] [Related]
6. Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis.
Amin R; Waters V
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD009249. PubMed ID: 27415821
[TBL] [Abstract][Full Text] [Related]
7. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.
Chuchalin A; Csiszér E; Gyurkovics K; Bartnicka MT; Sands D; Kapranov N; Varoli G; Monici Preti PA; Mazurek H
Paediatr Drugs; 2007; 9 Suppl 1():21-31. PubMed ID: 17536872
[TBL] [Abstract][Full Text] [Related]
8. Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols.
Taccetti G; Bianchini E; Cariani L; Buzzetti R; Costantini D; Trevisan F; Zavataro L; Campana S;
Thorax; 2012 Oct; 67(10):853-9. PubMed ID: 22379071
[TBL] [Abstract][Full Text] [Related]
9. The Effects of Antibiotic Combination Treatments on Pseudomonas aeruginosa Tolerance Evolution and Coexistence with Stenotrophomonas maltophilia.
Law JP; Wood AJ; Friman VP
Microbiol Spectr; 2022 Dec; 10(6):e0184222. PubMed ID: 36453898
[TBL] [Abstract][Full Text] [Related]
10. Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease.
Waters V; Yau Y; Prasad S; Lu A; Atenafu E; Crandall I; Tom S; Tullis E; Ratjen F
Am J Respir Crit Care Med; 2011 Mar; 183(5):635-40. PubMed ID: 20889901
[TBL] [Abstract][Full Text] [Related]
11. Biofilm compared to conventional antimicrobial susceptibility of Stenotrophomonas maltophilia Isolates from cystic fibrosis patients.
Wu K; Yau YC; Matukas L; Waters V
Antimicrob Agents Chemother; 2013 Mar; 57(3):1546-8. PubMed ID: 23295930
[TBL] [Abstract][Full Text] [Related]
12. Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis.
Amin R; Waters V
Cochrane Database Syst Rev; 2012 May; (5):CD009249. PubMed ID: 22592739
[TBL] [Abstract][Full Text] [Related]
13. Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients.
Waters V; Atenafu EG; Lu A; Yau Y; Tullis E; Ratjen F
J Cyst Fibros; 2013 Sep; 12(5):482-6. PubMed ID: 23294530
[TBL] [Abstract][Full Text] [Related]
14. Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis.
Amin R; Jahnke N; Waters V
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD009249. PubMed ID: 32189337
[TBL] [Abstract][Full Text] [Related]
15. Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis.
Amin R; Waters V
Cochrane Database Syst Rev; 2014 Apr; (4):CD009249. PubMed ID: 24696136
[TBL] [Abstract][Full Text] [Related]
16. Factors influencing the acquisition of Stenotrophomonas maltophilia infection in cystic fibrosis patients.
Stanojevic S; Ratjen F; Stephens D; Lu A; Yau Y; Tullis E; Waters V
J Cyst Fibros; 2013 Dec; 12(6):575-83. PubMed ID: 23757360
[TBL] [Abstract][Full Text] [Related]
17. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis.
Cheer SM; Waugh J; Noble S
Drugs; 2003; 63(22):2501-20. PubMed ID: 14609360
[TBL] [Abstract][Full Text] [Related]
18. Investigation of Stenotrophomonas maltophilia epidemiology in a French cystic fibrosis center.
Capaldo C; Beauruelle C; Saliou P; Rault G; Ramel S; Héry-Arnaud G
Respir Med Res; 2020 Nov; 78():100757. PubMed ID: 32759054
[TBL] [Abstract][Full Text] [Related]
19. Effects of tobramycin solution for inhalation on global ratings of quality of life in patients with cystic fibrosis and Pseudomonas aeruginosa infection.
Quittner AL; Buu A
Pediatr Pulmonol; 2002 Apr; 33(4):269-76. PubMed ID: 11921456
[TBL] [Abstract][Full Text] [Related]
20. Denitrification by cystic fibrosis pathogens - Stenotrophomonas maltophilia is dormant in sputum.
Kolpen M; Kragh KN; Bjarnsholt T; Line L; Hansen CR; Dalbøge CS; Hansen N; Kühl M; Høiby N; Jensen PØ
Int J Med Microbiol; 2015 Jan; 305(1):1-10. PubMed ID: 25441256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
